nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—JUN—psoriasis	0.509	1	CbGaD
Irbesartan—CYP2C8—Tazarotene—psoriasis	0.0381	0.135	CbGbCtD
Irbesartan—CYP1A2—Clobetasol propionate—psoriasis	0.0362	0.128	CbGbCtD
Irbesartan—CYP1A2—Methoxsalen—psoriasis	0.019	0.0674	CbGbCtD
Irbesartan—CYP2D6—Hydroxyurea—psoriasis	0.0171	0.0607	CbGbCtD
Irbesartan—CYP2C8—Cholecalciferol—psoriasis	0.0163	0.0577	CbGbCtD
Irbesartan—CYP2C8—Mycophenolate mofetil—psoriasis	0.0141	0.05	CbGbCtD
Irbesartan—CYP3A4—Calcitriol—psoriasis	0.0128	0.0454	CbGbCtD
Irbesartan—CYP2C9—Cholecalciferol—psoriasis	0.0113	0.0402	CbGbCtD
Irbesartan—CYP2C8—Hydrocortisone—psoriasis	0.0113	0.0401	CbGbCtD
Irbesartan—CYP2C8—Cyclosporine—psoriasis	0.0107	0.0379	CbGbCtD
Irbesartan—CYP2D6—Cholecalciferol—psoriasis	0.0104	0.0368	CbGbCtD
Irbesartan—CYP3A4—Methoxsalen—psoriasis	0.00995	0.0353	CbGbCtD
Irbesartan—CYP2C9—Cyclosporine—psoriasis	0.00745	0.0264	CbGbCtD
Irbesartan—CYP2C8—Dexamethasone—psoriasis	0.00703	0.0249	CbGbCtD
Irbesartan—CYP2D6—Cyclosporine—psoriasis	0.00681	0.0242	CbGbCtD
Irbesartan—CYP3A4—Cholecalciferol—psoriasis	0.00659	0.0234	CbGbCtD
Irbesartan—CYP3A4—Mycophenolate mofetil—psoriasis	0.00572	0.0203	CbGbCtD
Irbesartan—CYP3A4—Triamcinolone—psoriasis	0.00572	0.0203	CbGbCtD
Irbesartan—CYP2C9—Dexamethasone—psoriasis	0.00491	0.0174	CbGbCtD
Irbesartan—CYP3A4—Betamethasone—psoriasis	0.0049	0.0174	CbGbCtD
Irbesartan—CYP3A4—Prednisolone—psoriasis	0.00484	0.0172	CbGbCtD
Irbesartan—CYP3A4—Hydrocortisone—psoriasis	0.00459	0.0163	CbGbCtD
Irbesartan—CYP3A4—Prednisone—psoriasis	0.00457	0.0162	CbGbCtD
Irbesartan—CYP2D6—Dexamethasone—psoriasis	0.00449	0.0159	CbGbCtD
Irbesartan—CYP3A4—Cyclosporine—psoriasis	0.00433	0.0154	CbGbCtD
Irbesartan—CYP3A4—Dexamethasone—psoriasis	0.00285	0.0101	CbGbCtD
Irbesartan—JUN—skin epidermis—psoriasis	0.00106	0.272	CbGeAlD
Irbesartan—JUN—endothelium—psoriasis	0.000773	0.198	CbGeAlD
Irbesartan—AGTR1—endothelium—psoriasis	0.000582	0.149	CbGeAlD
Irbesartan—JUN—skin of body—psoriasis	0.00033	0.0843	CbGeAlD
Irbesartan—JUN—Dexamethasone—Clobetasol propionate—psoriasis	0.000298	0.0968	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Clobetasol propionate—psoriasis	0.000298	0.0968	CbGdCrCtD
Irbesartan—EDNRA—tendon—psoriasis	0.000275	0.0704	CbGeAlD
Irbesartan—PTGS1—endothelium—psoriasis	0.000256	0.0654	CbGeAlD
Irbesartan—JUN—tendon—psoriasis	0.000251	0.0642	CbGeAlD
Irbesartan—JUN—Betamethasone—Beclomethasone—psoriasis	0.000239	0.0775	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Fluocinonide—psoriasis	0.000239	0.0775	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Beclomethasone—psoriasis	0.000239	0.0775	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Fluocinonide—psoriasis	0.000239	0.0775	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000232	0.0754	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000232	0.0754	CbGdCrCtD
Irbesartan—AGTR1—tendon—psoriasis	0.000189	0.0483	CbGeAlD
Irbesartan—Losartan—ACE—psoriasis	0.000132	1	CrCbGaD
Irbesartan—JUN—Betamethasone—Hydrocortisone—psoriasis	0.000117	0.0381	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Hydrocortisone—psoriasis	0.000117	0.0381	CbGdCrCtD
Irbesartan—PTGS1—skin of body—psoriasis	0.000109	0.0279	CbGeAlD
Irbesartan—JUN—Dexamethasone—Betamethasone—psoriasis	0.000109	0.0353	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Dexamethasone—psoriasis	0.000109	0.0353	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Triamcinolone—psoriasis	0.000106	0.0345	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Triamcinolone—psoriasis	0.000106	0.0345	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisone—psoriasis	0.000101	0.0328	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisone—psoriasis	0.000101	0.0328	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisolone—psoriasis	9.85e-05	0.032	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisolone—psoriasis	9.85e-05	0.032	CbGdCrCtD
Irbesartan—PTGS1—tendon—psoriasis	8.31e-05	0.0213	CbGeAlD
Irbesartan—JUN—Cellular responses to stress—CAT—psoriasis	6.19e-05	0.000973	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NFKBIA—psoriasis	6.17e-05	0.00097	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CYP2S1—psoriasis	6.15e-05	0.000968	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—HCAR2—psoriasis	6.14e-05	0.000966	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—STAT3—psoriasis	6.13e-05	0.000965	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—NFKB1—psoriasis	6.12e-05	0.000962	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—TYK2—psoriasis	6.06e-05	0.000953	CbGpPWpGaD
Irbesartan—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.06e-05	0.000953	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—LEP—psoriasis	5.98e-05	0.000941	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—NFKB1—psoriasis	5.98e-05	0.00094	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—IL6—psoriasis	5.95e-05	0.000936	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CCL20—psoriasis	5.95e-05	0.000935	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	5.8e-05	0.000913	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—NFKB1—psoriasis	5.8e-05	0.000913	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	5.79e-05	0.00091	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	5.78e-05	0.000909	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—psoriasis	5.67e-05	0.000892	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—NFKB1—psoriasis	5.64e-05	0.000887	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—NOS2—psoriasis	5.57e-05	0.000876	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—CXCL8—psoriasis	5.56e-05	0.000875	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TNF—psoriasis	5.56e-05	0.000874	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CCL20—psoriasis	5.4e-05	0.000849	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—STAT3—psoriasis	5.37e-05	0.000845	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—STAT3—psoriasis	5.37e-05	0.000845	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—CXCL8—psoriasis	5.34e-05	0.00084	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TAGAP—psoriasis	5.33e-05	0.000838	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IFIH1—psoriasis	5.3e-05	0.000834	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—NFKB1—psoriasis	5.3e-05	0.000834	CbGpPWpGaD
Irbesartan—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.25e-05	0.000825	CbGpPWpGaD
Irbesartan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.22e-05	0.000822	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—PPARG—psoriasis	5.21e-05	0.000819	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL6—psoriasis	5.19e-05	0.000816	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—psoriasis	5.17e-05	0.000813	CbGpPWpGaD
Irbesartan—JUN—Immune System—ERAP1—psoriasis	5.1e-05	0.000802	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	5.05e-05	0.000795	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HLA-C—psoriasis	5.03e-05	0.000791	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—psoriasis	5e-05	0.000786	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TNFAIP3—psoriasis	4.97e-05	0.000781	CbGpPWpGaD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—IL6—psoriasis	4.91e-05	0.000773	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP53—psoriasis	4.9e-05	0.000771	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.87e-05	0.000766	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	4.81e-05	0.000756	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—NFKB1—psoriasis	4.78e-05	0.000751	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—psoriasis	4.76e-05	0.000749	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.76e-05	0.000748	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—NFKB1—psoriasis	4.72e-05	0.000743	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—STAT3—psoriasis	4.67e-05	0.000735	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—NFKB1—psoriasis	4.64e-05	0.00073	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—psoriasis	4.6e-05	0.000723	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—HCAR2—psoriasis	4.59e-05	0.000722	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL6—psoriasis	4.57e-05	0.000719	CbGpPWpGaD
Irbesartan—JUN—Immune System—DDX58—psoriasis	4.49e-05	0.000706	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—NFKB1—psoriasis	4.47e-05	0.000703	CbGpPWpGaD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—IL6—psoriasis	4.44e-05	0.000699	CbGpPWpGaD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—IL6—psoriasis	4.4e-05	0.000692	CbGpPWpGaD
Irbesartan—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.39e-05	0.000317	CcSEcCtD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	4.38e-05	0.000689	CbGpPWpGaD
Irbesartan—Urticaria—Cyclosporine—psoriasis	4.37e-05	0.000316	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.36e-05	0.000686	CbGpPWpGaD
Irbesartan—Myalgia—Betamethasone—psoriasis	4.36e-05	0.000315	CcSEcCtD
Irbesartan—Myalgia—Dexamethasone—psoriasis	4.36e-05	0.000315	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.36e-05	0.000685	CbGpPWpGaD
Irbesartan—Body temperature increased—Cyclosporine—psoriasis	4.35e-05	0.000314	CcSEcCtD
Irbesartan—Abdominal pain—Cyclosporine—psoriasis	4.35e-05	0.000314	CcSEcCtD
Irbesartan—Anxiety—Betamethasone—psoriasis	4.34e-05	0.000314	CcSEcCtD
Irbesartan—Anxiety—Dexamethasone—psoriasis	4.34e-05	0.000314	CcSEcCtD
Irbesartan—Vomiting—Mycophenolic acid—psoriasis	4.32e-05	0.000312	CcSEcCtD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	4.32e-05	0.00068	CbGpPWpGaD
Irbesartan—Discomfort—Dexamethasone—psoriasis	4.31e-05	0.000311	CcSEcCtD
Irbesartan—Discomfort—Betamethasone—psoriasis	4.31e-05	0.000311	CcSEcCtD
Irbesartan—Dyspepsia—Hydrocortisone—psoriasis	4.3e-05	0.000311	CcSEcCtD
Irbesartan—Rash—Mycophenolic acid—psoriasis	4.29e-05	0.00031	CcSEcCtD
Irbesartan—Dermatitis—Mycophenolic acid—psoriasis	4.28e-05	0.000309	CcSEcCtD
Irbesartan—Pain—Prednisolone—psoriasis	4.28e-05	0.000309	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—psoriasis	4.28e-05	0.000309	CcSEcCtD
Irbesartan—Urticaria—Mycophenolate mofetil—psoriasis	4.26e-05	0.000308	CcSEcCtD
Irbesartan—Headache—Mycophenolic acid—psoriasis	4.26e-05	0.000308	CcSEcCtD
Irbesartan—Decreased appetite—Hydrocortisone—psoriasis	4.25e-05	0.000307	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—psoriasis	4.25e-05	0.000307	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—IL6—psoriasis	4.24e-05	0.000668	CbGpPWpGaD
Irbesartan—Abdominal pain—Mycophenolate mofetil—psoriasis	4.24e-05	0.000306	CcSEcCtD
Irbesartan—Body temperature increased—Mycophenolate mofetil—psoriasis	4.24e-05	0.000306	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—CXCL8—psoriasis	4.23e-05	0.000665	CbGpPWpGaD
Irbesartan—Urinary tract disorder—Methotrexate—psoriasis	4.23e-05	0.000305	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.22e-05	0.000305	CcSEcCtD
Irbesartan—Fatigue—Hydrocortisone—psoriasis	4.22e-05	0.000305	CcSEcCtD
Irbesartan—Vision blurred—Prednisone—psoriasis	4.2e-05	0.000303	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—psoriasis	4.2e-05	0.000303	CcSEcCtD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—psoriasis	4.2e-05	0.00066	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.2e-05	0.000303	CcSEcCtD
Irbesartan—Pain—Hydrocortisone—psoriasis	4.18e-05	0.000302	CcSEcCtD
Irbesartan—Anaphylactic shock—Betamethasone—psoriasis	4.18e-05	0.000302	CcSEcCtD
Irbesartan—Oedema—Dexamethasone—psoriasis	4.18e-05	0.000302	CcSEcCtD
Irbesartan—Anaphylactic shock—Dexamethasone—psoriasis	4.18e-05	0.000302	CcSEcCtD
Irbesartan—Oedema—Betamethasone—psoriasis	4.18e-05	0.000302	CcSEcCtD
Irbesartan—JUN—Innate Immune System—HLA-E—psoriasis	4.17e-05	0.000656	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—STAT3—psoriasis	4.17e-05	0.000656	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—IL6—psoriasis	4.17e-05	0.000656	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	4.17e-05	0.000656	CbGpPWpGaD
Irbesartan—Infection—Dexamethasone—psoriasis	4.15e-05	0.0003	CcSEcCtD
Irbesartan—Infection—Betamethasone—psoriasis	4.15e-05	0.0003	CcSEcCtD
Irbesartan—Ill-defined disorder—Prednisone—psoriasis	4.14e-05	0.000299	CcSEcCtD
Irbesartan—Paraesthesia—Triamcinolone—psoriasis	4.13e-05	0.000299	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisolone—psoriasis	4.13e-05	0.000298	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—psoriasis	4.12e-05	0.000298	CcSEcCtD
Irbesartan—Anaemia—Prednisone—psoriasis	4.12e-05	0.000298	CcSEcCtD
Irbesartan—Shock—Betamethasone—psoriasis	4.11e-05	0.000297	CcSEcCtD
Irbesartan—Shock—Dexamethasone—psoriasis	4.11e-05	0.000297	CcSEcCtD
Irbesartan—Dyspnoea—Triamcinolone—psoriasis	4.11e-05	0.000297	CcSEcCtD
Irbesartan—JUN—MAPK Signaling Pathway—NFKB1—psoriasis	4.1e-05	0.000646	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	4.1e-05	0.000645	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—psoriasis	4.1e-05	0.000645	CbGpPWpGaD
Irbesartan—Nervous system disorder—Dexamethasone—psoriasis	4.1e-05	0.000296	CcSEcCtD
Irbesartan—Nervous system disorder—Betamethasone—psoriasis	4.1e-05	0.000296	CcSEcCtD
Irbesartan—Agitation—Prednisone—psoriasis	4.1e-05	0.000296	CcSEcCtD
Irbesartan—Thrombocytopenia—Dexamethasone—psoriasis	4.09e-05	0.000295	CcSEcCtD
Irbesartan—Thrombocytopenia—Betamethasone—psoriasis	4.09e-05	0.000295	CcSEcCtD
Irbesartan—Tachycardia—Dexamethasone—psoriasis	4.08e-05	0.000295	CcSEcCtD
Irbesartan—Tachycardia—Betamethasone—psoriasis	4.08e-05	0.000295	CcSEcCtD
Irbesartan—PTGS1—Metabolism—NDUFA5—psoriasis	4.07e-05	0.000641	CbGpPWpGaD
Irbesartan—Angioedema—Prednisone—psoriasis	4.07e-05	0.000294	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—CCL20—psoriasis	4.07e-05	0.00064	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—VEGFA—psoriasis	4.06e-05	0.000638	CbGpPWpGaD
Irbesartan—Hypersensitivity—Cyclosporine—psoriasis	4.05e-05	0.000293	CcSEcCtD
Irbesartan—Dyspepsia—Triamcinolone—psoriasis	4.05e-05	0.000293	CcSEcCtD
Irbesartan—Nausea—Mycophenolic acid—psoriasis	4.04e-05	0.000292	CcSEcCtD
Irbesartan—Hyperhidrosis—Dexamethasone—psoriasis	4.04e-05	0.000292	CcSEcCtD
Irbesartan—Hyperhidrosis—Betamethasone—psoriasis	4.04e-05	0.000292	CcSEcCtD
Irbesartan—Feeling abnormal—Hydrocortisone—psoriasis	4.03e-05	0.000291	CcSEcCtD
Irbesartan—Malaise—Prednisone—psoriasis	4.02e-05	0.00029	CcSEcCtD
Irbesartan—Vertigo—Prednisone—psoriasis	4.01e-05	0.000289	CcSEcCtD
Irbesartan—Gastrointestinal pain—Hydrocortisone—psoriasis	4e-05	0.000289	CcSEcCtD
Irbesartan—Syncope—Prednisone—psoriasis	4e-05	0.000289	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—psoriasis	3.99e-05	0.000288	CcSEcCtD
Irbesartan—Anorexia—Betamethasone—psoriasis	3.98e-05	0.000288	CcSEcCtD
Irbesartan—Anorexia—Dexamethasone—psoriasis	3.98e-05	0.000288	CcSEcCtD
Irbesartan—JUN—Signaling by NOTCH—TP53—psoriasis	3.98e-05	0.000626	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—psoriasis	3.98e-05	0.000626	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TAGAP—psoriasis	3.98e-05	0.000626	CbGpPWpGaD
Irbesartan—Urticaria—Prednisolone—psoriasis	3.98e-05	0.000287	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—psoriasis	3.97e-05	0.000287	CcSEcCtD
Irbesartan—Fatigue—Triamcinolone—psoriasis	3.97e-05	0.000287	CcSEcCtD
Irbesartan—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.96e-05	0.000286	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.95e-05	0.000622	CbGpPWpGaD
Irbesartan—Asthenia—Cyclosporine—psoriasis	3.95e-05	0.000285	CcSEcCtD
Irbesartan—Pain—Triamcinolone—psoriasis	3.94e-05	0.000284	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	3.94e-05	0.000619	CbGpPWpGaD
Irbesartan—JUN—MyD88-independent cascade—IL6—psoriasis	3.93e-05	0.000619	CbGpPWpGaD
Irbesartan—Loss of consciousness—Prednisone—psoriasis	3.92e-05	0.000283	CcSEcCtD
Irbesartan—Hypotension—Dexamethasone—psoriasis	3.9e-05	0.000282	CcSEcCtD
Irbesartan—Hypotension—Betamethasone—psoriasis	3.9e-05	0.000282	CcSEcCtD
Irbesartan—Pruritus—Cyclosporine—psoriasis	3.89e-05	0.000281	CcSEcCtD
Irbesartan—Urticaria—Hydrocortisone—psoriasis	3.89e-05	0.000281	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—psoriasis	3.88e-05	0.00028	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—psoriasis	3.87e-05	0.000279	CcSEcCtD
Irbesartan—Abdominal pain—Hydrocortisone—psoriasis	3.87e-05	0.000279	CcSEcCtD
Irbesartan—Body temperature increased—Hydrocortisone—psoriasis	3.87e-05	0.000279	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—psoriasis	3.86e-05	0.000279	CcSEcCtD
Irbesartan—Asthenia—Mycophenolate mofetil—psoriasis	3.85e-05	0.000278	CcSEcCtD
Irbesartan—Hypertension—Prednisone—psoriasis	3.85e-05	0.000278	CcSEcCtD
Irbesartan—Chills—Methotrexate—psoriasis	3.84e-05	0.000277	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL6—psoriasis	3.84e-05	0.000604	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.81e-05	0.000275	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Betamethasone—psoriasis	3.81e-05	0.000275	CcSEcCtD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.8e-05	0.000598	CbGpPWpGaD
Irbesartan—Pruritus—Mycophenolate mofetil—psoriasis	3.8e-05	0.000274	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—STAT3—psoriasis	3.8e-05	0.000597	CbGpPWpGaD
Irbesartan—Arthralgia—Prednisone—psoriasis	3.8e-05	0.000274	CcSEcCtD
Irbesartan—Myalgia—Prednisone—psoriasis	3.8e-05	0.000274	CcSEcCtD
Irbesartan—Feeling abnormal—Triamcinolone—psoriasis	3.79e-05	0.000274	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—NFKB1—psoriasis	3.78e-05	0.000595	CbGpPWpGaD
Irbesartan—Anxiety—Prednisone—psoriasis	3.78e-05	0.000273	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.77e-05	0.000272	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.77e-05	0.000593	CbGpPWpGaD
Irbesartan—Diarrhoea—Cyclosporine—psoriasis	3.77e-05	0.000272	CcSEcCtD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—IL6—psoriasis	3.75e-05	0.00059	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IL6—psoriasis	3.75e-05	0.00059	CbGpPWpGaD
Irbesartan—Paraesthesia—Dexamethasone—psoriasis	3.75e-05	0.000271	CcSEcCtD
Irbesartan—Paraesthesia—Betamethasone—psoriasis	3.75e-05	0.000271	CcSEcCtD
Irbesartan—Discomfort—Prednisone—psoriasis	3.75e-05	0.000271	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.74e-05	0.000588	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	3.73e-05	0.000587	CbGpPWpGaD
Irbesartan—Malnutrition—Methotrexate—psoriasis	3.73e-05	0.000269	CcSEcCtD
Irbesartan—Erythema—Methotrexate—psoriasis	3.73e-05	0.000269	CcSEcCtD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	3.72e-05	0.000584	CbGpPWpGaD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—psoriasis	3.71e-05	0.000583	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.7e-05	0.000583	CbGpPWpGaD
Irbesartan—Hypersensitivity—Prednisolone—psoriasis	3.69e-05	0.000266	CcSEcCtD
Irbesartan—Dyspepsia—Betamethasone—psoriasis	3.68e-05	0.000266	CcSEcCtD
Irbesartan—Dyspepsia—Dexamethasone—psoriasis	3.68e-05	0.000266	CcSEcCtD
Irbesartan—Diarrhoea—Mycophenolate mofetil—psoriasis	3.67e-05	0.000265	CcSEcCtD
Irbesartan—Urticaria—Triamcinolone—psoriasis	3.66e-05	0.000264	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—psoriasis	3.65e-05	0.000264	CcSEcCtD
Irbesartan—Body temperature increased—Triamcinolone—psoriasis	3.64e-05	0.000263	CcSEcCtD
Irbesartan—Dizziness—Cyclosporine—psoriasis	3.64e-05	0.000263	CcSEcCtD
Irbesartan—Oedema—Prednisone—psoriasis	3.64e-05	0.000263	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—psoriasis	3.64e-05	0.000263	CcSEcCtD
Irbesartan—Decreased appetite—Betamethasone—psoriasis	3.63e-05	0.000262	CcSEcCtD
Irbesartan—Decreased appetite—Dexamethasone—psoriasis	3.63e-05	0.000262	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.63e-05	0.000571	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CXCL8—psoriasis	3.62e-05	0.00057	CbGpPWpGaD
Irbesartan—Infection—Prednisone—psoriasis	3.61e-05	0.000261	CcSEcCtD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.61e-05	0.000567	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Betamethasone—psoriasis	3.61e-05	0.000261	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Dexamethasone—psoriasis	3.61e-05	0.000261	CcSEcCtD
Irbesartan—Hypersensitivity—Hydrocortisone—psoriasis	3.6e-05	0.00026	CcSEcCtD
Irbesartan—Fatigue—Betamethasone—psoriasis	3.6e-05	0.00026	CcSEcCtD
Irbesartan—Fatigue—Dexamethasone—psoriasis	3.6e-05	0.00026	CcSEcCtD
Irbesartan—Shock—Prednisone—psoriasis	3.58e-05	0.000259	CcSEcCtD
Irbesartan—Pain—Betamethasone—psoriasis	3.57e-05	0.000258	CcSEcCtD
Irbesartan—Pain—Dexamethasone—psoriasis	3.57e-05	0.000258	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—psoriasis	3.57e-05	0.000258	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—psoriasis	3.55e-05	0.000256	CcSEcCtD
Irbesartan—Dizziness—Mycophenolate mofetil—psoriasis	3.55e-05	0.000256	CcSEcCtD
Irbesartan—JUN—Activated TLR4 signalling—IL6—psoriasis	3.54e-05	0.000557	CbGpPWpGaD
Irbesartan—Skin disorder—Prednisone—psoriasis	3.53e-05	0.000255	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—psoriasis	3.52e-05	0.000254	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—psoriasis	3.51e-05	0.000254	CcSEcCtD
Irbesartan—Asthenia—Hydrocortisone—psoriasis	3.51e-05	0.000253	CcSEcCtD
Irbesartan—Vomiting—Cyclosporine—psoriasis	3.5e-05	0.000253	CcSEcCtD
Irbesartan—JUN—Innate Immune System—SOCS1—psoriasis	3.49e-05	0.000548	CbGpPWpGaD
Irbesartan—Rash—Cyclosporine—psoriasis	3.47e-05	0.000251	CcSEcCtD
Irbesartan—Anorexia—Prednisone—psoriasis	3.47e-05	0.000251	CcSEcCtD
Irbesartan—Dermatitis—Cyclosporine—psoriasis	3.47e-05	0.00025	CcSEcCtD
Irbesartan—PTGS1—Metabolism—CYP2S1—psoriasis	3.46e-05	0.000545	CbGpPWpGaD
Irbesartan—Pruritus—Hydrocortisone—psoriasis	3.46e-05	0.00025	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—psoriasis	3.46e-05	0.00025	CcSEcCtD
Irbesartan—Headache—Cyclosporine—psoriasis	3.45e-05	0.000249	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—psoriasis	3.44e-05	0.000249	CcSEcCtD
Irbesartan—Feeling abnormal—Betamethasone—psoriasis	3.44e-05	0.000249	CcSEcCtD
Irbesartan—Feeling abnormal—Dexamethasone—psoriasis	3.44e-05	0.000249	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dexamethasone—psoriasis	3.42e-05	0.000247	CcSEcCtD
Irbesartan—Gastrointestinal pain—Betamethasone—psoriasis	3.42e-05	0.000247	CcSEcCtD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—psoriasis	3.41e-05	0.000537	CbGpPWpGaD
Irbesartan—Vomiting—Mycophenolate mofetil—psoriasis	3.41e-05	0.000247	CcSEcCtD
Irbesartan—JUN—Immune System—ITGAL—psoriasis	3.4e-05	0.000535	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—STAT3—psoriasis	3.4e-05	0.000535	CbGpPWpGaD
Irbesartan—Hypersensitivity—Triamcinolone—psoriasis	3.39e-05	0.000245	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—psoriasis	3.39e-05	0.000533	CbGpPWpGaD
Irbesartan—Rash—Mycophenolate mofetil—psoriasis	3.38e-05	0.000244	CcSEcCtD
Irbesartan—Dermatitis—Mycophenolate mofetil—psoriasis	3.38e-05	0.000244	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—VEGFA—psoriasis	3.38e-05	0.000531	CbGpPWpGaD
Irbesartan—Headache—Mycophenolate mofetil—psoriasis	3.36e-05	0.000243	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.36e-05	0.000529	CbGpPWpGaD
Irbesartan—Malaise—Methotrexate—psoriasis	3.36e-05	0.000243	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—psoriasis	3.35e-05	0.000242	CcSEcCtD
Irbesartan—Diarrhoea—Hydrocortisone—psoriasis	3.35e-05	0.000242	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—psoriasis	3.34e-05	0.000241	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	3.33e-05	0.000523	CbGpPWpGaD
Irbesartan—Urticaria—Dexamethasone—psoriasis	3.32e-05	0.00024	CcSEcCtD
Irbesartan—Urticaria—Betamethasone—psoriasis	3.32e-05	0.00024	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—psoriasis	3.32e-05	0.000239	CcSEcCtD
Irbesartan—Dizziness—Prednisolone—psoriasis	3.31e-05	0.000239	CcSEcCtD
Irbesartan—Asthenia—Triamcinolone—psoriasis	3.3e-05	0.000239	CcSEcCtD
Irbesartan—Abdominal pain—Betamethasone—psoriasis	3.3e-05	0.000239	CcSEcCtD
Irbesartan—Body temperature increased—Betamethasone—psoriasis	3.3e-05	0.000239	CcSEcCtD
Irbesartan—Body temperature increased—Dexamethasone—psoriasis	3.3e-05	0.000239	CcSEcCtD
Irbesartan—Abdominal pain—Dexamethasone—psoriasis	3.3e-05	0.000239	CcSEcCtD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.29e-05	0.000518	CbGpPWpGaD
Irbesartan—Nausea—Cyclosporine—psoriasis	3.27e-05	0.000236	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—psoriasis	3.27e-05	0.000236	CcSEcCtD
Irbesartan—Pruritus—Triamcinolone—psoriasis	3.26e-05	0.000235	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—TP53—psoriasis	3.26e-05	0.000512	CbGpPWpGaD
Irbesartan—Cough—Methotrexate—psoriasis	3.25e-05	0.000235	CcSEcCtD
Irbesartan—Dizziness—Hydrocortisone—psoriasis	3.23e-05	0.000234	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—psoriasis	3.2e-05	0.000231	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—CXCL8—psoriasis	3.19e-05	0.000503	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—psoriasis	3.19e-05	0.000502	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CCL20—psoriasis	3.19e-05	0.000502	CbGpPWpGaD
Irbesartan—Nausea—Mycophenolate mofetil—psoriasis	3.19e-05	0.00023	CcSEcCtD
Irbesartan—JUN—Immune System—REL—psoriasis	3.18e-05	0.000501	CbGpPWpGaD
Irbesartan—Arthralgia—Methotrexate—psoriasis	3.17e-05	0.000229	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—psoriasis	3.17e-05	0.000229	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—psoriasis	3.17e-05	0.000229	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—psoriasis	3.16e-05	0.000228	CcSEcCtD
Irbesartan—Rash—Prednisolone—psoriasis	3.16e-05	0.000228	CcSEcCtD
Irbesartan—Dermatitis—Prednisolone—psoriasis	3.15e-05	0.000228	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.15e-05	0.000228	CcSEcCtD
Irbesartan—Fatigue—Prednisone—psoriasis	3.14e-05	0.000227	CcSEcCtD
Irbesartan—Headache—Prednisolone—psoriasis	3.14e-05	0.000227	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—psoriasis	3.13e-05	0.000226	CcSEcCtD
Irbesartan—Constipation—Prednisone—psoriasis	3.11e-05	0.000225	CcSEcCtD
Irbesartan—Vomiting—Hydrocortisone—psoriasis	3.11e-05	0.000225	CcSEcCtD
Irbesartan—JUN—Immune System—IFIH1—psoriasis	3.09e-05	0.000486	CbGpPWpGaD
Irbesartan—Rash—Hydrocortisone—psoriasis	3.08e-05	0.000223	CcSEcCtD
Irbesartan—Dermatitis—Hydrocortisone—psoriasis	3.08e-05	0.000222	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—psoriasis	3.07e-05	0.000482	CbGpPWpGaD
Irbesartan—Headache—Hydrocortisone—psoriasis	3.06e-05	0.000221	CcSEcCtD
Irbesartan—Dizziness—Triamcinolone—psoriasis	3.05e-05	0.00022	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—psoriasis	3.04e-05	0.00022	CcSEcCtD
Irbesartan—Infection—Methotrexate—psoriasis	3.02e-05	0.000218	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	3.02e-05	0.000475	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CARM1—psoriasis	3e-05	0.000473	CbGpPWpGaD
Irbesartan—Feeling abnormal—Prednisone—psoriasis	3e-05	0.000217	CcSEcCtD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	3e-05	0.000472	CbGpPWpGaD
Irbesartan—Asthenia—Betamethasone—psoriasis	3e-05	0.000217	CcSEcCtD
Irbesartan—Asthenia—Dexamethasone—psoriasis	3e-05	0.000217	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—psoriasis	2.98e-05	0.000215	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—psoriasis	2.98e-05	0.000215	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—psoriasis	2.98e-05	0.000215	CcSEcCtD
Irbesartan—Nausea—Prednisolone—psoriasis	2.97e-05	0.000215	CcSEcCtD
Irbesartan—JUN—Innate Immune System—HLA-B—psoriasis	2.97e-05	0.000468	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—IL6—psoriasis	2.96e-05	0.000466	CbGpPWpGaD
Irbesartan—Pruritus—Betamethasone—psoriasis	2.96e-05	0.000214	CcSEcCtD
Irbesartan—Pruritus—Dexamethasone—psoriasis	2.96e-05	0.000214	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—psoriasis	2.95e-05	0.000213	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—psoriasis	2.94e-05	0.000212	CcSEcCtD
Irbesartan—JUN—Immune System—HLA-C—psoriasis	2.93e-05	0.000461	CbGpPWpGaD
Irbesartan—Vomiting—Triamcinolone—psoriasis	2.93e-05	0.000211	CcSEcCtD
Irbesartan—Nausea—Hydrocortisone—psoriasis	2.9e-05	0.00021	CcSEcCtD
Irbesartan—Rash—Triamcinolone—psoriasis	2.9e-05	0.00021	CcSEcCtD
Irbesartan—Dermatitis—Triamcinolone—psoriasis	2.9e-05	0.00021	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—psoriasis	2.9e-05	0.000209	CcSEcCtD
Irbesartan—JUN—Immune System—TNFAIP3—psoriasis	2.89e-05	0.000455	CbGpPWpGaD
Irbesartan—Urticaria—Prednisone—psoriasis	2.89e-05	0.000209	CcSEcCtD
Irbesartan—Headache—Triamcinolone—psoriasis	2.88e-05	0.000208	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.88e-05	0.000453	CbGpPWpGaD
Irbesartan—Body temperature increased—Prednisone—psoriasis	2.88e-05	0.000208	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—psoriasis	2.88e-05	0.000208	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—NFKB1—psoriasis	2.86e-05	0.00045	CbGpPWpGaD
Irbesartan—Diarrhoea—Betamethasone—psoriasis	2.86e-05	0.000206	CcSEcCtD
Irbesartan—Diarrhoea—Dexamethasone—psoriasis	2.86e-05	0.000206	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—CXCL8—psoriasis	2.84e-05	0.000447	CbGpPWpGaD
Irbesartan—Hypotension—Methotrexate—psoriasis	2.84e-05	0.000205	CcSEcCtD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	2.83e-05	0.000445	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.82e-05	0.000444	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.82e-05	0.000444	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—psoriasis	2.81e-05	0.000443	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Methotrexate—psoriasis	2.77e-05	0.0002	CcSEcCtD
Irbesartan—Dizziness—Dexamethasone—psoriasis	2.76e-05	0.0002	CcSEcCtD
Irbesartan—Dizziness—Betamethasone—psoriasis	2.76e-05	0.0002	CcSEcCtD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	2.75e-05	0.000432	CbGpPWpGaD
Irbesartan—Nausea—Triamcinolone—psoriasis	2.74e-05	0.000198	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL6—psoriasis	2.73e-05	0.00043	CbGpPWpGaD
Irbesartan—Paraesthesia—Methotrexate—psoriasis	2.73e-05	0.000197	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—psoriasis	2.71e-05	0.000196	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—psoriasis	2.7e-05	0.000195	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisone—psoriasis	2.68e-05	0.000194	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—psoriasis	2.68e-05	0.000193	CcSEcCtD
Irbesartan—Vomiting—Betamethasone—psoriasis	2.66e-05	0.000192	CcSEcCtD
Irbesartan—Vomiting—Dexamethasone—psoriasis	2.66e-05	0.000192	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—psoriasis	2.64e-05	0.000191	CcSEcCtD
Irbesartan—Rash—Dexamethasone—psoriasis	2.63e-05	0.00019	CcSEcCtD
Irbesartan—Rash—Betamethasone—psoriasis	2.63e-05	0.00019	CcSEcCtD
Irbesartan—Dermatitis—Dexamethasone—psoriasis	2.63e-05	0.00019	CcSEcCtD
Irbesartan—Dermatitis—Betamethasone—psoriasis	2.63e-05	0.00019	CcSEcCtD
Irbesartan—CYP2C8—Metabolism—NDUFA5—psoriasis	2.63e-05	0.000414	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CRP—psoriasis	2.63e-05	0.000413	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Methotrexate—psoriasis	2.63e-05	0.00019	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—psoriasis	2.62e-05	0.000189	CcSEcCtD
Irbesartan—Headache—Dexamethasone—psoriasis	2.62e-05	0.000189	CcSEcCtD
Irbesartan—Headache—Betamethasone—psoriasis	2.62e-05	0.000189	CcSEcCtD
Irbesartan—Asthenia—Prednisone—psoriasis	2.61e-05	0.000189	CcSEcCtD
Irbesartan—Pain—Methotrexate—psoriasis	2.6e-05	0.000188	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—VEGFA—psoriasis	2.59e-05	0.000408	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—psoriasis	2.59e-05	0.000408	CbGpPWpGaD
Irbesartan—Pruritus—Prednisone—psoriasis	2.57e-05	0.000186	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—STAT3—psoriasis	2.57e-05	0.000404	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.54e-05	0.0004	CbGpPWpGaD
Irbesartan—Feeling abnormal—Methotrexate—psoriasis	2.51e-05	0.000181	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—psoriasis	2.49e-05	0.00018	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—psoriasis	2.49e-05	0.00018	CcSEcCtD
Irbesartan—Nausea—Dexamethasone—psoriasis	2.48e-05	0.000179	CcSEcCtD
Irbesartan—Nausea—Betamethasone—psoriasis	2.48e-05	0.000179	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.47e-05	0.000389	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.45e-05	0.000386	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—psoriasis	2.44e-05	0.000384	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-E—psoriasis	2.43e-05	0.000382	CbGpPWpGaD
Irbesartan—Urticaria—Methotrexate—psoriasis	2.42e-05	0.000174	CcSEcCtD
Irbesartan—Dizziness—Prednisone—psoriasis	2.41e-05	0.000174	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—psoriasis	2.4e-05	0.000174	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—psoriasis	2.4e-05	0.000174	CcSEcCtD
Irbesartan—JUN—Innate Immune System—NFKBIA—psoriasis	2.4e-05	0.000377	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL20—psoriasis	2.38e-05	0.000375	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—IL6—psoriasis	2.37e-05	0.000374	CbGpPWpGaD
Irbesartan—Vomiting—Prednisone—psoriasis	2.31e-05	0.000167	CcSEcCtD
Irbesartan—Rash—Prednisone—psoriasis	2.29e-05	0.000166	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—psoriasis	2.29e-05	0.000166	CcSEcCtD
Irbesartan—Headache—Prednisone—psoriasis	2.28e-05	0.000165	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—psoriasis	2.24e-05	0.000162	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—SOCS1—psoriasis	2.24e-05	0.000352	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CYP2S1—psoriasis	2.24e-05	0.000352	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—IL6—psoriasis	2.23e-05	0.000351	CbGpPWpGaD
Irbesartan—Asthenia—Methotrexate—psoriasis	2.18e-05	0.000158	CcSEcCtD
Irbesartan—Nausea—Prednisone—psoriasis	2.16e-05	0.000156	CcSEcCtD
Irbesartan—CYP2D6—Metabolism—NDUFA5—psoriasis	2.16e-05	0.00034	CbGpPWpGaD
Irbesartan—Pruritus—Methotrexate—psoriasis	2.15e-05	0.000155	CcSEcCtD
Irbesartan—CYP2C9—Metabolism—NDUFA5—psoriasis	2.14e-05	0.000337	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TYK2—psoriasis	2.13e-05	0.000336	CbGpPWpGaD
Irbesartan—Diarrhoea—Methotrexate—psoriasis	2.08e-05	0.00015	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL8—psoriasis	2.05e-05	0.000322	CbGpPWpGaD
Irbesartan—JUN—Immune System—SOCS1—psoriasis	2.03e-05	0.000319	CbGpPWpGaD
Irbesartan—Dizziness—Methotrexate—psoriasis	2.01e-05	0.000145	CcSEcCtD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2e-05	0.000314	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TYK2—psoriasis	1.96e-05	0.000309	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—psoriasis	1.96e-05	0.000308	CbGpPWpGaD
Irbesartan—Vomiting—Methotrexate—psoriasis	1.93e-05	0.00014	CcSEcCtD
Irbesartan—Rash—Methotrexate—psoriasis	1.92e-05	0.000138	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—psoriasis	1.92e-05	0.000138	CcSEcCtD
Irbesartan—Headache—Methotrexate—psoriasis	1.91e-05	0.000138	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—CXCL8—psoriasis	1.86e-05	0.000292	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CAT—psoriasis	1.85e-05	0.000291	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CYP2S1—psoriasis	1.84e-05	0.000289	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NDUFA5—psoriasis	1.83e-05	0.000288	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CYP2S1—psoriasis	1.82e-05	0.000286	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.82e-05	0.000286	CbGpPWpGaD
Irbesartan—Nausea—Methotrexate—psoriasis	1.81e-05	0.00013	CcSEcCtD
Irbesartan—JUN—Immune System—CD8A—psoriasis	1.8e-05	0.000283	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—IL6—psoriasis	1.79e-05	0.000282	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD4—psoriasis	1.78e-05	0.000279	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SOCS1—psoriasis	1.76e-05	0.000276	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-B—psoriasis	1.73e-05	0.000272	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.71e-05	0.000268	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CARM1—psoriasis	1.69e-05	0.000266	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TYK2—psoriasis	1.67e-05	0.000263	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—LEP—psoriasis	1.65e-05	0.00026	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—APOE—psoriasis	1.65e-05	0.00026	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL8—psoriasis	1.61e-05	0.000253	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-A—psoriasis	1.6e-05	0.000252	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.58e-05	0.000249	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CYP2S1—psoriasis	1.56e-05	0.000245	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NFKBIA—psoriasis	1.54e-05	0.000242	CbGpPWpGaD
Irbesartan—JUN—Immune System—CRP—psoriasis	1.53e-05	0.000241	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NFKB1—psoriasis	1.53e-05	0.000241	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-DRB1—psoriasis	1.47e-05	0.000231	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL8—psoriasis	1.46e-05	0.000229	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—APOE—psoriasis	1.44e-05	0.000226	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NDUFA5—psoriasis	1.41e-05	0.000222	CbGpPWpGaD
Irbesartan—JUN—Immune System—ICAM1—psoriasis	1.41e-05	0.000221	CbGpPWpGaD
Irbesartan—JUN—Immune System—NFKBIA—psoriasis	1.4e-05	0.00022	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SOCS1—psoriasis	1.31e-05	0.000206	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—APOE—psoriasis	1.3e-05	0.000204	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—LEP—psoriasis	1.3e-05	0.000204	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TYK2—psoriasis	1.26e-05	0.000198	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PPARG—psoriasis	1.25e-05	0.000197	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NFKBIA—psoriasis	1.21e-05	0.00019	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP2S1—psoriasis	1.2e-05	0.000189	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.17e-05	0.000184	CbGpPWpGaD
Irbesartan—JUN—Immune System—TYK2—psoriasis	1.14e-05	0.00018	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL8—psoriasis	1.1e-05	0.000173	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CARM1—psoriasis	1.09e-05	0.000172	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNG—psoriasis	1.07e-05	0.000168	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL6—psoriasis	1.04e-05	0.000164	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CAT—psoriasis	1.04e-05	0.000164	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—psoriasis	1.03e-05	0.000163	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.02e-05	0.000161	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—JUN—psoriasis	1.02e-05	0.000161	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TYK2—psoriasis	9.89e-06	0.000156	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—NFKB1—psoriasis	9.82e-06	0.000155	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—LEP—psoriasis	9.69e-06	0.000152	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APOE—psoriasis	9.69e-06	0.000152	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—psoriasis	9.6e-06	0.000151	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.54e-06	0.00015	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NFKBIA—psoriasis	9.03e-06	0.000142	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CARM1—psoriasis	8.97e-06	0.000141	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—psoriasis	8.92e-06	0.00014	CbGpPWpGaD
Irbesartan—JUN—Immune System—NFKB1—psoriasis	8.91e-06	0.00014	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CARM1—psoriasis	8.89e-06	0.00014	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—psoriasis	8.83e-06	0.000139	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—psoriasis	8.62e-06	0.000136	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.31e-06	0.000131	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—psoriasis	8.19e-06	0.000129	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.16e-06	0.000128	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOE—psoriasis	8.09e-06	0.000127	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—JUN—psoriasis	8.01e-06	0.000126	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—psoriasis	8.01e-06	0.000126	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NFKB1—psoriasis	7.71e-06	0.000121	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CARM1—psoriasis	7.6e-06	0.00012	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TYK2—psoriasis	7.39e-06	0.000116	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.1e-06	0.000112	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—psoriasis	7.04e-06	0.000111	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—psoriasis	7e-06	0.00011	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—psoriasis	6.93e-06	0.000109	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—psoriasis	6.74e-06	0.000106	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAT—psoriasis	6.72e-06	0.000106	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—psoriasis	6.44e-06	0.000101	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—psoriasis	6.17e-06	9.7e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CARM1—psoriasis	5.87e-06	9.23e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NFKB1—psoriasis	5.76e-06	9.06e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—psoriasis	5.59e-06	8.8e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAT—psoriasis	5.52e-06	8.68e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAT—psoriasis	5.47e-06	8.61e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—psoriasis	5.29e-06	8.32e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—psoriasis	5.23e-06	8.22e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOE—psoriasis	5.22e-06	8.22e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—psoriasis	5.18e-06	8.14e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—psoriasis	4.84e-06	7.61e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAT—psoriasis	4.68e-06	7.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—psoriasis	4.55e-06	7.16e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOE—psoriasis	4.29e-06	6.74e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOE—psoriasis	4.25e-06	6.69e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—psoriasis	3.95e-06	6.21e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—psoriasis	3.73e-06	5.87e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—psoriasis	3.7e-06	5.82e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOE—psoriasis	3.63e-06	5.71e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—psoriasis	3.62e-06	5.69e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAT—psoriasis	3.61e-06	5.68e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—psoriasis	3.16e-06	4.98e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOE—psoriasis	2.8e-06	4.41e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—psoriasis	2.44e-06	3.84e-05	CbGpPWpGaD
